Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The 'U.S. Gene Therapy Market Size, Share & Trends Analysis Report by Indication (Multiple Myeloma, Spinal Muscular Atrophy, Inherited Retinal Disease), Route Of Administration, Vector Type (Lentivirus, AAV, Adenovirus), and Segment Forecasts, 2024-2030' report has been added to ResearchAndMarkets.com's offering.The U.S.

都柏林，2024年4月23日（环球通讯社）——ResearchAndMarkets.com的产品中增加了“2024-2030年美国基因治疗市场规模、份额和趋势分析报告（按适应症（多发性骨髓瘤、脊髓性肌萎缩症、遗传性视网膜疾病）、给药途径、载体类型（慢病毒、AAV、腺病毒）和细分市场预测”。

gene therapy market size is anticipated to reach USD 10.40 billion by 2030, expanding at a CAGR of 19.21% during 2024-2030 The market growth can be attributed to various factors such as the expanding area of advanced therapies along with gene delivery technologies and increased competition among key players focused on the commercialization of their therapies.

预计到2030年，基因治疗市场规模将达到104.0亿美元，2024-2030年的复合年增长率将达到19.21%。市场增长可归因于各种因素，例如先进疗法领域的扩大以及基因传递技术，以及专注于其疗法商业化的关键参与者之间的竞争加剧。

Similar to many other industries, the COVID-19 pandemic has had an impact on the U.S. market for gene therapy. While the market is expected to grow significantly in the coming years, the pandemic has caused delays in clinical trials and disruptions in the supply chain. The pandemic also highlighted the importance of gene therapy in treating and preventing diseases, which could lead to increased funding and investment in the field.

与许多其他行业类似，新型冠状病毒肺炎对美国基因治疗市场产生了影响。虽然预计未来几年市场将大幅增长，但这种流行病已导致临床试验延迟和供应链中断。这种流行病还突出了基因治疗在治疗和预防疾病方面的重要性，这可能导致该领域的资金和投资增加。

Overall, while the pandemic has caused some challenges for the U.S. gene therapy industry, there is still significant potential for growth and advancement in the coming years.The gene therapy pipeline in the U.S. is currently quite robust, with several promising therapies in various stages of development.

总的来说，虽然这一流行病给美国基因治疗行业带来了一些挑战，但在未来几年中仍有巨大的增长和进步潜力。美国的基因治疗渠道目前相当强大，在不同的发展阶段有几种有前途的疗法。

Many of these therapies focus on rare genetic diseases, such as spinal muscular atrophy, choroideremia, Duchenne muscular dystrophy, and hemophilia. In addition, gene editing technologies like CRISPR-Cas9 are being used to develop therapies that can target specific genetic mutations with greater precision.

这些疗法中的许多都专注于罕见的遗传疾病，例如脊髓性肌萎缩症，脉络膜血症，杜兴氏肌营养不良症和血友病。此外，CRISPR-Cas9等基因编辑技术正在用于开发可以更精确地靶向特定基因突变的疗法。

For instance, in.

例如，在。

Attachment

附件

U.S. Gene Therapy Market

U、 美国基因治疗市场